KNBIF Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.01 and $0.03. With a market capitalization of about $3.81 million, Kane Biotech Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.31). Key stats such as the average daily volume over the past year has been around 138.51 thousand shares, volume is running light vs its 52-week average. Headquartered in Winnipeg, MB, Kane Biotech Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Huizinga, the company employs approximately 20 people and listed since August 07, 2007. Kane Biotech Inc. is a biotechnology firm specializing in the research, development, and global commercialization of innovative technologies and products focused on preventing and eradicating microbial biofilms.

Average 10-day trading volume of 27.50 thousand shares is below the 3-month average of 318.01 thousand, indicating normal recent market interest.

Kane Biotech Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.06. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Kane Biotech Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Kane Biotech Inc. trading at a premium to the broader market with a P/E of -1.78.

Kane Biotech Inc. trades at a P/E ratio of -1.78, slightly below the S&P 500 average, with a price-to-sales ratio of 137.42 and a price-to-book ratio of -5.32 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.2, also below market averages.